OBJECTIVES: To describe the use of the Jupiter scleral contact lens (Medlens Innovations, Front Royal, VA or Essilor Contact Lens, Inc., Dallas, TX) in the management of ocular manifestations of chronic graft versus host disease (cGVHD). METHODS: This study is a retrospective case series. Five consecutive patients with severe keratoconjunctivitis sicca (KCS) associated with cGVHD that could not be adequately managed with conventional therapy were evaluated for scleral contact lens wear between January and December 2007. All patients were evaluated with lenses from the standard 18.2 mm Jupiter B diagnostic fitting set. If lenses of standard design failed to provide adequate fit, custom lenses were designed. Three outcome measures were evaluated: the patient's ability to tolerate and successfully handle the lenses, improvement in symptoms of KCS, and improvement in visual acuity. RESULTS: All 5 patients (10 eyes) were successfully fit with Jupiter scleral lenses. Six eyes of 3 patients were successfully fit with lenses of standard design. Standard parameters were altered to achieve adequate fit in 4 eyes of 2 patients. All patients reported subjective improvements in comfort with Jupiter scleral lenses, and best-corrected vision improved in 7 of the 10 eyes fit within the first several months of contact lens wear. The remaining 3 eyes maintained the visual acuity measured before scleral lens wear (20/20 in 2 eyes, 20/40 in 1 eye). Duration of follow-up ranged from 4 to 14 months. CONCLUSIONS: Jupiter scleral lenses can relieve symptoms of KCS and may improve vision in patients with cGVHD.
OBJECTIVES: To describe the use of the Jupiter scleral contact lens (Medlens Innovations, Front Royal, VA or Essilor Contact Lens, Inc., Dallas, TX) in the management of ocular manifestations of chronic graft versus host disease (cGVHD). METHODS: This study is a retrospective case series. Five consecutive patients with severe keratoconjunctivitis sicca (KCS) associated with cGVHD that could not be adequately managed with conventional therapy were evaluated for scleral contact lens wear between January and December 2007. All patients were evaluated with lenses from the standard 18.2 mm Jupiter B diagnostic fitting set. If lenses of standard design failed to provide adequate fit, custom lenses were designed. Three outcome measures were evaluated: the patient's ability to tolerate and successfully handle the lenses, improvement in symptoms of KCS, and improvement in visual acuity. RESULTS: All 5 patients (10 eyes) were successfully fit with Jupiter scleral lenses. Six eyes of 3 patients were successfully fit with lenses of standard design. Standard parameters were altered to achieve adequate fit in 4 eyes of 2 patients. All patients reported subjective improvements in comfort with Jupiter scleral lenses, and best-corrected vision improved in 7 of the 10 eyes fit within the first several months of contact lens wear. The remaining 3 eyes maintained the visual acuity measured before scleral lens wear (20/20 in 2 eyes, 20/40 in 1 eye). Duration of follow-up ranged from 4 to 14 months. CONCLUSIONS: Jupiter scleral lenses can relieve symptoms of KCS and may improve vision in patients with cGVHD.
Authors: L Magro; J Gauthier; M Richet; M Robin; S Nguyen; F Suarez; J-H Dalle; T Fagot; A Huynh; M-T Rubio; R Oumadely; S Vigouroux; N Milpied; A Delcampe; I Yakoub-Agha Journal: Bone Marrow Transplant Date: 2017-02-20 Impact factor: 5.483
Authors: Paul A Carpenter; Carrie L Kitko; Sharon Elad; Mary E D Flowers; Juan C Gea-Banacloche; Jörg P Halter; Flora Hoodin; Laura Johnston; Anita Lawitschka; George B McDonald; Anthony W Opipari; Bipin N Savani; Kirk R Schultz; Sean R Smith; Karen L Syrjala; Nathaniel Treister; Georgia B Vogelsang; Kirsten M Williams; Steven Z Pavletic; Paul J Martin; Stephanie J Lee; Daniel R Couriel Journal: Biol Blood Marrow Transplant Date: 2015-03-31 Impact factor: 5.742
Authors: Kavitha R Sivaraman; Renu V Jivrajka; Ketki Soin; Charles S Bouchard; Asadolah Movahedan; Ellen Shorter; Sandeep Jain; Deborah S Jacobs; Ali R Djalilian Journal: Ocul Surf Date: 2016-05-12 Impact factor: 5.033
Authors: Hualei Zhai; Paulo J M Bispo; Hidenaga Kobashi; Deborah S Jacobs; Michael S Gilmore; Joseph B Ciolino Journal: Am J Ophthalmol Case Rep Date: 2018-09-12
Authors: Shannon M Bligdon; Bradley A Colarusso; Allen Y Ganjei; Alan Kwok; Zhonghui Katie Luo; Daniel Brocks Journal: Clin Ophthalmol Date: 2021-12-25